title: Differential expression of interferon-γ and chemokine genes distinguishes Rasmussen encephalitis from cortical dysplasia and provides evidence for an early Th1 immune response.
abstract: BACKGROUND
  Rasmussen encephalitis (RE) is a rare complex inflammatory disease, primarily seen in young children, that is characterized by severe partial seizures and brain atrophy. Surgery is currently the only effective treatment option. To identify genes specifically associated with the immunopathology in RE, RNA transcripts of genes involved in inflammation and autoimmunity were measured in brain tissue from RE surgeries and compared with those in surgical specimens of cortical dysplasia (CD), a major cause of intractable pediatric epilepsy.
  
  
  METHODS
  Quantitative polymerase chain reactions measured the relative expression of 84 genes related to inflammation and autoimmunity in 12 RE specimens and in the reference group of 12 CD surgical specimens. Data were analyzed by consensus clustering using the entire dataset, and by pairwise comparison of gene expression levels between the RE and CD cohorts using the Harrell-Davis distribution-free quantile estimator method.
  
  
  RESULTS
  Consensus clustering identified six RE cases that were clearly distinguished from the CD cases and from other RE cases. Pairwise comparison showed that seven mRNAs encoding interferon-γ, CCL5, CCL22, CCL23, CXCL9, CXCL10, and Fas ligand were higher in the RE specimens compared with the CD specimens, whereas the mRNA encoding hypoxanthine-guanine phosphoribosyltransferase was reduced. Interferon-γ, CXCL5, CXCL9 and CXCL10 mRNA levels negatively correlated with time from seizure onset to surgery (P <0.05), whereas CCL23 and Fas ligand transcript levels positively correlated with the degree of tissue destruction and inflammation, respectively (P <0.05), as determined from magnetic resonance imaging (MRI) T2 and FLAIR images. Accumulation of CD4+ lymphocytes in leptomeninges and perivascular spaces was a prominent feature in RE specimens resected within a year of seizure onset.
  
  
  CONCLUSIONS
  Active disease is characterized by a Th1 immune response that appears to involve both CD8+ and CD4+ T cells. Our findings suggest therapeutic intervention targeting specific chemokine/chemokine receptors may be useful in early stage RE.
authors: Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. geoffreyowens@mednet.ucla.edu
authors: Geoffrey C
authors: GC
authors: Owens
authors: My N
authors: MN
authors: Huynh
authors: Julia W
authors: JW
authors: Chang
authors: David L
authors: DL
authors: McArthur
authors: Michelle J
authors: MJ
authors: Hickey
authors: Harry V
authors: HV
authors: Vinters
authors: Gary W
authors: GW
authors: Mathern
authors: Carol A
authors: CA
authors: Kruse
mesh_terms: D000293:Adolescent; D017668:Age of Onset; D000465:Algorithms; D015153:Blotting, Western; D018925:Chemokines / Q000096:biosynthesis* / Q000235:genetics; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D004660:Encephalitis / Q000235:genetics* / Q000473:pathology; D004827:Epilepsy / Q000209:etiology; D005260:Female; D007839:Functional Laterality; D038421:Hemispherectomy; D006801:Humans; D007223:Infant; D007371:Interferon-gamma / Q000096:biosynthesis* / Q000235:genetics; D008279:Magnetic Resonance Imaging; D008297:Male; D054220:Malformations of Cortical Development / Q000235:genetics* / Q000473:pathology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D018417:Th1 Cells / Q000276:immunology*
chemical_list: D018925:Chemokines; D012333:RNA, Messenger; D007371:Interferon-gamma
references: Neuropathol Appl Neurobiol. 2003 Dec;29(6):584-95
references: 14636165
references: Ann Neurol. 2002 Mar;51(3):311-8
references: 11891826
references: Brain. 2009 May;132(Pt 5):1247-58
references: 19179377
references: Clin Neuropathol. 1995 Jan-Feb;14(1):7-12
references: 7729084
references: Epilepsia. 2010 Sep;51(9):1763-73
references: 20345941
references: Eur J Neurol. 2007 Apr;14(4):387-90
references: 17388985
references: Lancet. 1989 Feb 4;1(8632):279-80
references: 2563444
references: Hum Pathol. 1993 Aug;24(8):871-9
references: 8397159
references: J Bioinform Comput Biol. 2010 Oct;8(5):885-900
references: 20981893
references: PLoS Pathog. 2011 Nov;7(11):e1002393
references: 22114563
references: Cell Mol Immunol. 2013 Jan;10(1):30-4
references: 23085943
references: Cancer Res. 2004 Aug 1;64(15):5245-50
references: 15289330
references: Neurology. 2005 Dec 13;65(11):1802-4
references: 16344526
references: Neuropathol Appl Neurobiol. 2010 Aug;36(5):368-87
references: 20487305
references: Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4164-9
references: 15016911
references: Nat Rev Immunol. 2009 Jun;9(6):393-407
references: 19444307
references: Adv Immunol. 2007;96:41-101
references: 17981204
references: J Neuroimmunol. 2002 Oct;131(1-2):179-85
references: 12458050
references: Lancet. 1990 Nov 24;336(8726):1282-4
references: 1978116
references: Epilepsy Res. 2008 Jul;80(1):93-7
references: 18440783
references: Epilepsia. 2011 May;52 Suppl 3:5-11
references: 21542839
references: Int Immunol. 1999 Jan;11(1):81-8
references: 10050676
references: J Immunol. 2003 Sep 1;171(5):2637-43
references: 12928417
references: J Neurosci Res. 2003 May 15;72(4):472-86
references: 12704809
references: Neurology. 2002 Jan 22;58(2):250-7
references: 11805253
references: Am J Clin Pathol. 2002 May;117(5):776-82
references: 12090428
references: Eur J Immunol. 2000 Dec;30(12):3623-33
references: 11169405
references: Epilepsia. 2011 Jan;52(1):158-74
references: 21219302
references: Neurology. 1958 Jun;8(6):435-45
references: 13566382
references: Prog Neurobiol. 2011 Oct;95(2):229-74
references: 21907261
references: Brain Res. 1993 Aug 13;619(1-2):157-62
references: 8374773
references: Eur J Immunol. 2006 Jul;36(7):1654-8
references: 16791883
references: Epilepsia. 1993 Jul-Aug;34(4):639-50
references: 8330574
references: Immunol Cell Biol. 2011 Feb;89(2):207-15
references: 21221121
references: Neurobiol Dis. 2009 Jun;34(3):432-40
references: 19285133
references: Nat Rev Immunol. 2004 Aug;4(8):595-602
references: 15286726
references: Neurology. 2010 Jun 1;74(22):1768-75
references: 20427752
references: Epilepsia. 2009 Jun;50(6):1419-31
references: 19175398
references: Epilepsia. 2005;46 Suppl 5:152-8
references: 15987271
references: Ann Neurol. 2007 Jul;62(1):67-80
references: 17503512
references: Neurology. 2004 Jul 13;63(1):43-50
references: 15249609
references: Endocr Metab Immune Disord Drug Targets. 2009 Dec;9(4):315-27
references: 20028334
references: J Neuroinflammation. 2009 Dec 19;6:38
references: 20021679
references: J Neuroimmunol. 2002 Jul;128(1-2):9-15
references: 12098505
references: Neurology. 1995 Jan;45(1):108-17
references: 7824098
references: Eur J Immunol. 2013 Jan;43(1):115-24
references: 23011975
references: Hum Pathol. 2012 Aug;43(8):1308-13
references: 22401768
references: J Neuroimmunol. 2002 Sep;130(1-2):10-21
references: 12225884
references: Curr Opin Immunol. 2004 Jun;16(3):259-63
references: 15134772
references: Nat Rev Immunol. 2011 May;11(5):355-63
references: 21494268
references: Epilepsia. 2004 May;45(5):516-26
references: 15101833
references: Blood. 1998 May 1;91(9):3118-26
references: 9558365
references: J Neurochem. 2004 Jul;90(2):297-308
references: 15228586
references: Adv Neurol. 1992;57:419-33
references: 1543071
references: Annu Rev Immunol. 2010;28:445-89
references: 20192806
references: Science. 1994 Jul 29;265(5172):648-51
references: 8036512
references: Neurology. 2001 Oct 23;57(8):1511-4
references: 11673604
references: J Neuroinflammation. 2012 Dec 17;9:270
references: 23244217
references: Neurosci Lett. 2003 Mar 13;339(1):62-6
references: 12618301
references: Acta Neuropathol. 1995;89(4):313-21
references: 7610762